|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Petawatt and exawatt class lasers worldwide显示文摘In the 2015 review paper‘Petawatt Class Lasers Worldwide’a comprehensive overview of the current status of highpower facilities of>200 TW was presented.This was largely based on facility specifications,with some description of their uses,for instance in fundamental ultra-high-intensity interactions,secondary source generation,and inertial confinement fusion(ICF).With the 2018 Nobel Prize in Physics being awarded to Professors Donna Strickland and Gerard Mourou for the development of the technique of chirped pulse amplification(CPA),which made these lasers possible,we celebrate by providing a comprehensive update of the current status of ultra-high-power lasers and demonstrate how the technology has developed.We are now in the era of multi-petawatt facilities coming online,with 100 PW lasers being proposed and even under construction.In addition to this there is a pull towards development of industrial and multi-disciplinary applications,which demands much higher repetition rates,delivering high-average powers with higher efficiencies and the use of alternative wavelengths:mid-IR facilities.So apart from a comprehensive update of the current global status,we want to look at what technologies are to be deployed to get to these new regimes,and some of the critical issues facing their development. | Colin N.Danson Constantin Haefner Jake Bromage Thomas Butcher Jean-Christophe FChanteloup Enam A.Chowdhury Almantas Galvanauskas Leonida A.Gizzi Joachim Hein David I.Hillier Nicholas W.Hopps Yoshiaki Kato Efim A.Khazanov Ryosuke Kodama Georg Korn Ruxin Li Yutong Li Jens Limpert Jingui Ma Chang Hee Nam David Neely Dimitrios Papadopoulos Rory R.Penman Liejia Qian Jorge J.Rocca andrey A.Shaykin Craig W.Siders Christopher Spindloe Sándor Szatmári Raoul M.G.M.Trines Jianqiang Zhu Ping Zhu Jonathan D.Zuegel | 2019 | High Power Laser Science and Engineering2019，7，3： | 33 |
| 2 | Short‐term versus long‐term induction therapy with antithymocyte globulin in orthotopic liver transplantation显示文摘 | Thomas Soliman Hubert Hetz Christoph Burghuber Georg Gy?ri Gerd Silberhumer Rudolf Steininger Ferdinand Mühlbacher Gabriela A. Berlakovich | 2007 | Transplant International2007，，5： | 1 |
| 3 | Surface electronic properties on boron doped(111) CVD homoepitaxial diamond films after oxidation treatments显示文摘 | Sung-Gi Ri Daisuke Takeuchi Christoph E | 2007 | Diamond Related Mater2007，16，47： | 1 |
| 4 | Effects of dietary curcumin on glutathione s-tranaferase and malondialdehyde-DNA adducts in rat liver and colon mucosa: relationship with drug levelsl 显示文摘 | Ricky AS Christopher RI Richard DV | 2001 | Clin Cancer Res2001，7，： | 1 |
| 5 | Galileo civil signal modulations显示文摘 | Emilie Rebeyrol Olivier Julien Christophe Macabiau Lionel Ries Antoine Delatour Laurent Lestarquit | 2007 | GPS Solutions2007，，3： | 1 |
| 6 | Measuring agile capabilities in the supply chain 显示文摘 | Van Hoek RI Harrison A Christopher MG | 2001 | International Journal of Operations and Production Management2001，21，12： | 1 |
| 7 | Surface electronic properties on boron doped (111) CVD homoepitaxial diamond films after oxidation treatments显示文摘 | Sung-Gi Ri Daisuke Takeuchi Christoph E | 2007 | Diamond Relat Mater2007，16，47： | 1 |
| 8 | Cost-analysis of inpatient and outpatient parenteral antimicrobial therapy in orthopaedics: A systematic literature review显示文摘BACKGROUND Increasing numbers of total joint arthroplasties and consecutive revision surgery are associated with the risk of periprosthetic joint infections (PPJI). Treatment of PPJI is complex and associated with immense socio-economic burden. One treatment aspect is parenteral antiinfective therapy, which usually requires an inpatient setting [Inpatient parenteral antibiotic therapy (IPAT)]. An alternative is outpatient parenteral treatment [Outpatient parenteral antibiotic therapy (OPAT)]. To conduct a health economic cost-benefit analysis of OPAT, a detailed cost analysis of IPAT and OPAT is required. So far, there is a lack of knowledge on the health economic effects of IPAT and OPAT for PPJI. AIM To review an economic comparison of IPAT and OPAT. METHODS A systematic literature review was performed through Medline following the PRISMA guidelines. RESULTS Of 619 identified studies, 174 included information of interest and 21 studies were included for quantitative analysis of OPAT and IPAT costs. Except for one study, all showed relevant cost savings for OPAT compared to IPAT. Costs for IPAT were between 1.10 to 17.34 times higher than those for OPAT. CONCLUSION There are only few reports on OPAT for PPJI. Detailed analyses to support economic or clinical guidelines are therefore limited. There is good clinical evidence supporting economic benefits of OPAT, but more high quality studies are needed for PPJI. | Christoph Kolja Boese Philipp Lechler Michael Frink Michael Hackl Peer Eysel Christian Ries | 2019 | World Journal of Clinical Cases2019，7，14： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员